Literature DB >> 2533474

Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.

R Koshida1, S Cox, J Harmenberg, G Gilljam, B Wahren.   

Abstract

One hundred nucleoside analogs with fluorine substitutions at various positions on the pentose ring were evaluated for inhibitory activity against human immunodeficiency virus type 1 (HIV-1). Nine compounds emerged as inhibitors of HIV-1 replication, with various degrees of selectivity; the most active of these was 3'-fluoro-3'-deoxythymidine, followed by 5'-amino-3'-fluoro-3'-deoxyadenosine. Substitution of fluorine at the 2'-deoxy or 3'-deoxy position resulted in increased antiviral activity of the thymidine analogs, whereas the activity of adenosine or cytidine analogs was not increased by fluorination at either position. The most potent inhibitor, 3'-fluoro-3'-deoxythymidine, was shown to give synergistic inhibition of HIV-1 replication in combination with the PPi analog phosphonoformate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533474      PMCID: PMC172825          DOI: 10.1128/AAC.33.12.2083

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  Antiviral therapy.

Authors:  B Oberg
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

2.  An analysis of the inhibition of replication of HIV and MuLV by some 3'-blocked pyrimidine analogs.

Authors:  H Bazin; J Chattopadhyaya; R Datema; A C Ericson; G Gilljam; N G Johansson; J Hansen; R Koshida; K Moelling; B Oberg
Journal:  Biochem Pharmacol       Date:  1989-01-01       Impact factor: 5.858

3.  Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues.

Authors:  J Balzarini; M Baba; R Pauwels; P Herdewijn; E De Clerq
Journal:  Biochem Pharmacol       Date:  1988-07-15       Impact factor: 5.858

4.  2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV).

Authors:  V E Marquez; C K Tseng; J A Kelley; H Mitsuya; S Broder; J S Roth; J S Driscoll
Journal:  Biochem Pharmacol       Date:  1987-09-01       Impact factor: 5.858

5.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

6.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

7.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

8.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Authors:  T Haertle; C J Carrera; D B Wasson; L C Sowers; D D Richman; D A Carson
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

9.  Potent and selective activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside, 3'-fluoro-2,6-diaminopurine-2',3'-dideoxyriboside, and 3'-fluoro-2',3'-dideoxyguanosine against human immunodeficiency virus.

Authors:  J Balzarini; M Baba; R Pauwels; P Herdewijn; S G Wood; M J Robins; E de Clercq
Journal:  Mol Pharmacol       Date:  1988-03       Impact factor: 4.436

10.  Investigations on the anti-HIV activity of 2',3'-dideoxyadenosine analogues with modifications in either the pentose or purine moiety. Potent and selective anti-HIV activity of 2,6-diaminopurine 2',3'-dideoxyriboside.

Authors:  R Pauwels; M Baba; J Balzarini; P Herdewijn; J Desmyter; M J Robins; R M Zou; D Madej; E De Clercq
Journal:  Biochem Pharmacol       Date:  1988-04-01       Impact factor: 5.858

View more
  7 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Demonstration of Nucleoside Transporter Activity in the Nose-to-Brain Distribution of [18F]Fluorothymidine Using PET Imaging.

Authors:  Laura L Boles Ponto; Jiangeng Huang; Susan A Walsh; Michael R Acevedo; Christine Mundt; John Sunderland; Maureen Donovan
Journal:  AAPS J       Date:  2017-12-07       Impact factor: 4.009

Review 4.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope.

Authors:  M Ohlin; J Hinkula; P A Broliden; R Grunow; C A Borrebaeck; B Wahren
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

6.  Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action.

Authors:  E Ljungdahl-Ståhle; E Guzenda; D Böttiger; B Wahren; B Oberg; L Ståhle
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Synthesis, Antiviral, and Antimicrobial Evaluation of Benzyl Protected Diversified C-nucleosides.

Authors:  Ahmed Bari; Syed S Ali; Amer M Alanazi; Muhammad A Mashwani; Abdulrahman M Al-Obaid
Journal:  Front Chem       Date:  2018-07-19       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.